AzTrials
AzTrials

Stroke SequelaePoCH-RehabNCT06436898

Proof of Concept of Hybrid Robotics for Gait Rehabilitation of Persons Post-stroke

A study testing Combined overground gait exoskeleton and FES applied to lower limb and Overground gait exoskeleton in people with Stroke Sequelae and Gait, Hemiplegic, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Persons post-stroke suffer from hemiparesis affecting the functional abilities of the controlesional lower limb. Improving walking is therefore a primary rehabilitation goal for such patients. Robotic-Assisted Rehabilitation (RAR, e.g. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Stroke Sequelae, Gait, Hemiplegic
What is being tested?
Combined overground gait exoskeleton and FES applied to lower limb and Overground gait exoskeleton
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteItaly
Study dates
1 Sep 2024to 1 Nov 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 18 years or older
  • Diagnosis of first unilateral ischemic or hemorrhagic ictus, at least two weeks from the event, ischemic or hemorrhagic
  • diagnosis confermed with Computer Tomography or Magnetic Resonance Imaging
  • 1 ≤ FAC (Functional ambulation category) ≤ 3
  • 50 kg ≤ weight ≤ 90 kg
  • 150 cm ≤ height ≤ 192 cm
Show all 11Show fewer
  • Femor length: 355-475 mm
  • Tibia length: 405-485 mm
  • Pelvic width 690-990 mm
  • shoe size 36-45
  • Capable of standing unsupported for at least one minute

Who cannot join

  • Mini Mental State Examination score (corrected for age and education) < 24
  • Clinical evidence in the medical records of visuospatial and ideomotor apraxia, behavioral disorders, neglect, severe visual and auditory sensory disorders or those which prevent use of the device
  • patients at risk of fractures or with strategic fractures (unstabilized fractures or spinal instability)
  • Major head trauma
  • Subarachnoid hemorrhage, cerebral thrombosis
  • Cardio-respiratory or internal clinical instability
Show all 15Show fewer
  • Pregnant or breastfeeding status;
  • Recent malignant neoplasm
  • Chronic inflammatory diseases with joint involvement of the lower limbs;
  • Severe spasticity (Ashworth>3)
  • Significant limitations in passive ROM of the hips and knees
  • Problems with the integrity of the skin at the interface surfaces with the device or which would prevent sitting.
  • Implanted electronic devices
  • Epilepsy
  • Severe peripheral neuropathies

Trial locations and contacts

1 site in 1 country.

Tiziana Lencioni, PhD contact

024030 ext. 8547

tlencioni@dongnocchi.it

Johanna Jonsdottir, PhD contact

024030 ext. 8840

jjonsdottir@dongnocchi.it

Italy1 site
  • Fondazione Don Carlo Gnocchi IRCCS

    Milan, 20148

Other trials in Italy

About this study

Official title: Proof of Concept of Hybrid Robotics for Gait Rehabilitation of Persons Post-stroke (PoCH-Rehab)

Persons post-stroke suffer from hemiparesis affecting the functional abilities of the controlesional lower limb. Improving walking is therefore a primary rehabilitation goal for such patients. Robotic-Assisted Rehabilitation (RAR, e.g. exoskeletons) and Functional Electrical Stimulation (FES) are promising techniques to facilitate the functional recovery after stroke. allowing benefits to be maintained over long term.

Read the detailed description

Exoskeletons were originally developed for subjects with spinal cord injury where they demonstrated a positive impact on rehabilitation and relative costs. The investigators expect the same trend also for stroke. Based on prior exploratory activities using an overgorund exoskeleton (TWIN_Acta) in gait rehabilitation post stroke, in this project the aim is to merge the potential of an overground exoskeleton and FES to treat the lower limb motor deficits in persons post-stroke, strengthening their residual abilities. Synchronized pairing of the two devices might boost the functional recovery of gait post-stroke by promoting neural reorganization The persons post stroke will undergo 20 gait rehabiliation sessions with the exoskeleton and with FES applied to the lower limb muscles during execution of gait with the aim of improving various gait and quality of life parameters. This experimental intervention will be compared to a control intervention using an exoskeleton alone for gait rehabiltation post stroke.

Being tested
Combined overground gait exoskeleton and FES applied to lower limb, Overground gait exoskeleton
Keywords
Gait rehabilitation, Exoskeleton, Functional Electrical Stimulation, Hemiplegia, Overground
Medical subject headings
Gait Disorders, Neurologic, Hemiplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Combined overground gait exoskeleton and FES applied to lower limbDevice

    Also called TWIN_Acta and FITFES

    Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.

  • Overground gait exoskeletonDevice

    Also called TWIN_Acta

    Gait rehabilitation for persons with stroke, with an overground exoskeleton.

Study groups in NCT06436898
Study groupRoleWhat they receive
Exoskeleton plus FESExperimentalParticipants will train gait with an overground exoskeleton and a combined myoelectrically controlled Functional Electrostimulation System (FES) applied to lower limb muscles during execution of gait.
Receives: Device: Combined overground gait exoskeleton and FES applied to lower limb
ExoskeletonActive comparatorParticipants will train gait with an overground exoskeleton.
Receives: Device: Overground gait exoskeleton

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. System Usability scale (SUS)

    The SUS assesses Usability and Acceptability of a device. The SUS consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. The scores will be normalized to produce a percentile ranking. The higher the percentage the better the tested device is considiered.

    Measured: At baseline and at post after 4 weeks of intervention

  2. Velocity of gait

    Gait velocity during 3D gait analysis measured while walking overground over 10 meters. Velocity is measured in meters/second

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

Secondary outcomes (21)
  1. Motricity Index Lower limb (MI LL)

    The motricity index is an ordinal method fo measuring limb strength. Maximum total lower limb score is 99. Scoring goes from 0 no movement to 33 normal power.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  2. Fugl Meyer Assessment of motor recovery after stroke. Lower limb (FMA LL)

    The scale evaluates and measures neuromotor recovery in post stroke patients. Items are scored on a 3-point ordinal scale, from 0 cannot perform to score 2 performs fully. Maximum score for lower limb is 34.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  3. Functional Ambulation Category (FAC)

    The FAC assesses functional ambulation in patients undergoing physical therapy. The clinician ticks a box of 5 broad categories of walking ability from not being able to walk or needing help from to or more persons to score of 5 if they can walk independently anywhere.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  4. Stroke Rehabilitation Motivation Scale (7-item SRMS)

    The 7-item SRMS was devised from the 28-item SRMS and inquires upon intrinsic and extrinsic motivation domains for rehabilitation. Scores range from 1 to 7 so the total score can range from 7-35 with higher scores indicating higher motivation.

    Measured: At baseline and at post after 4 weeks of intervention

  5. Fatigue Severity Scale (FSS)

    The impact of fatigue on day-to-day function is measured using the Fatigue Severity Scale (FSS). This measure is a self-report scale with nine questions answered on a 7-point Likert scale. The FSS score is reported as one total score which is the mean of the nine items. Scores range from 1 to 7 and higher scores indicate greater impact of fatigue on daily life.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  6. Ashworth scale

    The Modified Ashworth Scale (MAS) is a revised version of the original Ashworth Scale that measures spasticity in patients with lesions to the central nervous system. MAS is an assessment that is used to measure the increase in muscle tone. MAS assigns a grade of spasticity from a 0-4 ordinal scale with higher score indicating more spasticity. The grade is assigned by moving a joint/muscle through a high velocity quick stretch.Spasticity of calf and knee muscles will be tested

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  7. Manual muscle test (MMT)

    MMT is a standardized set of assessments that measure muscle strength and function. Score range 0-5, minimum 0, maximum 5/5 meaning normal strength. Strength of calf and knee muscles will be tested.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  8. Five times sit to stand test (5TStS)

    The Five Times Sit to Stand Test measures one aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. Patient is timed while standing up and sitting down 5 times in row.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  9. Timed up and go test (TUG)

    The Timed Up and Go Test (TUG) assesses mobility, balance, walking ability, and fall risk. Patient are timed while standing up from a chair walking 3 meters, turning around, walking 3 meters and sitting down again.

    The patient sits in the chair with his/her back against the chair back. On the command "go," the patient rises from the chair, walks 3 meters at a comfortable and safe pace, turns, walks back to the chair and sits down.

    Timing begins at the instruction "go" and stops when the patient is seated.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  10. Two minutes walking test (2MWT)

    Walking capcaity is measured with the Participant timed while walking a 30 meter track constantly for 2 minutes. Participants are permitted to use their walking aids if necessary. The distance walked in 2 minutes is recorded and reported in metres

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  11. 10 meter walking test (10MVT)

    Walking speed is measured by the timed 10 m Walk Test (10MWT). Participants walk a distance of 10 m at their usual speed with their usual walking aids. Participants are timed while walking 10 meters from a starting point to an end point. Time taken from meter 2 to meter 8. Two repetitions are completed and the average time is used to calcualte walking speed in metres/second.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  12. The walking handicap scale (WHS)

    The walking handicap scale is a questionnaire asking subjective gait skills. The scale goes from 1 to 6, with score 1 being a physiological gait only with a physiotherapist, to score 6 being unrestricted community ambulation gait.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  13. Beck Depression Inventory-II (BDI-II)

    the BDI-II is a patient reported outcome that quantifies severity of depression. BDI-II identifies overt behavioral characteristics of depression. Items are on a four-point scale that ranges from 0 to 3. Ratings are summed to provide a total score ranging from 0 - 63. Scores >10 generally meet the threshold for a diagnosis of depression.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  14. Unified Theory of Acceptance and Use of Technology (UTAUT)

    A questionnaire asking how acceptable and easy to use the technological device is. The theoretical model of UTAUT suggests that the actual use of technology is determined by behavioural intention. The perceived likelihood of adopting the technology is dependent on the direct effect of four key constructs, namely performance expectancy, effort expectancy, social influence, and facilitating conditions. The UTAUT examines the acceptance of technology, determined by the effects of performance expectancy, effort expectancy, social influence and facilitating conditions.

    Measured: At baseline and at post after 4 weeks of intervention

  15. Report of adverse events

    Organized reporting of adverse events occurring during the use of the device

    Measured: at baseline and at post after 4 weeks of intervention

  16. Euro Quality of Life-5 -dimension Questionnaire (EQ-5D-5L)

    EQ-5D-FL is a standardized instrument for use as a measure of health for clinical and economic appraisal.Applicable to a wide range of health conditions and treatments, the EQ-5D health questionnaire provides a simple descriptive profile and a single index value for health status.

    Measures the 5 dimensions of:

    1. mobility
    2. self-care
    3. usual activities
    4. pain/discomfort
    5. anxiety/depression Each dimension is scored on a Likert scale of 5 levels, with higher scores indicating more severe problems.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  17. Motion parameters derived from the kinematics of the body

    Lower limb data will be captured utilizing two wearable Inertia Measurement Units (IMUs) operating at 280 Hz. These IMUs will be placed on both feet to analyze spatio-temporal gait characteristics. Through data processing, deviations from typical movement patterns will be quantified.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  18. Postural capabilities will be evaluated based on body kinetics

    Postural data of the lower limb will be acquired using an optoelectronic system combined with two force plates, sampling at 2000 Hz. Utilizing data processing techniques, deviations from normal postural dynamics will be determined.

    Measured: At baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  19. Muscular synergies

    Muscle synergies will be extracted from the Electromyography (EMG) envelope of each participant detected during overground gait employing the Non-Negative Matrix Factorization algorithm. Treatment-induced changes in the resemblance of muscle synergies to physiological patterns will be assessed. Module similarity will be gauged through the maximum scalar product of muscle weightings between each participant and the normative reference. Additionally, the activation profile similarity will be measured using the Pearson's correlation coefficient of each module's activation profile.

    Measured: at baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  20. Instrumented 2 Minute Walk test (I2MWT)

    Changes in the I2MWT will be evaluated through IMU sampling at 280 Hz positioned on the lower back. Deviations from the typical performance observed in healthy subjects will be evaluated.

    Measured: at baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

  21. Instrumented Timed Up and Go (ITUG)

    Changes in the instrumented Timed Up and Go (ITUG) test will be examined. The TUG test will be administered with an IMU sampling at 280 Hz positioned on the lower back. Deviations from the typical performance observed in healthy subjects will be evaluated.

    Measured: at baseline, at post after 4 weeks of intervention, at follow up after 8 weeks from the end of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 May 2024
  2. Study start1 Sep 2024 (estimated)
  3. Primary completion1 Jul 2025 (estimated)
  4. Study completion1 Nov 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06436898
Sponsor's protocol ID
PoCH-Rehab
Acronym
PoCH-Rehab
Status last verified
May 2024
First submitted
16 Feb 2024
Last updated
31 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be available upon request

Questions about this trial

What is this clinical trial studying?

A study testing Combined overground gait exoskeleton and FES applied to lower limb and Overground gait exoskeleton in people with Stroke Sequelae and Gait, Hemiplegic, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 31 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tiziana Lencioni, PhD (024030 ext. 8547, tlencioni@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

System Usability scale (SUS) (time frame: At baseline and at post after 4 weeks of intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in